期刊文献+

环孢素A固体脂质纳米粒的制备与理化性质考察 被引量:5

Studies on preparation of cyclosporin SLN and its physical-chemical properties
下载PDF
导出
摘要 目的探讨以环孢素(cyclosporin A,CyA)为模型药物的多肽类药物固体脂质纳米粒(SLN)的制备并研究其理化性质方法以CyA为模型药物,选用甘油三硬脂酸酯,采用溶剂扩散法制备甘油三酸酯纳米粒,测定其粒径分布、表面电位、药物包封率考察不同的制备工艺对SLN粒径及包封率的影响,并进行载药纳米粒的体外释放实验结果以CyA为模型药物,用水性溶剂扩散法可以简便、快速制得甘油三硬脂酸酯固体脂质纳米粒,体均粒径为(142.5±120.2)nm,包封率为58.42% 并且通过调节pH的方法,在高速离心(25 000 r·min-1)条件下,即可达到纳米粒与分散体系之间的有效分离甘油三硬脂酸酯纳米粒在最初的6 h有药物的突释现象,在随后的8 d内药物的释放明显减缓,每天释放约药物总量的5.7% 加入5%和10%聚乙二醇(PEG)的SLN能明显加快药物的释放。结论经溶剂扩散法制备并通过加入一定比例PEG。 OBJECTIVE: To study the preparation and physicochemical characteristics of cyclosporin SLN. METHODS: A stable SLN was prepared using triglyceride by solvent diffusion method in aqueous system. The lipophilic model drug, cyclosporin, was incorporated. The entrapment efficacy, Zeta potential (charge), drug delivery characterization were measured. Various preparation processes of SLN were carried out to investigate their effect on particle size, entrapment efficacy and drug release profiles of SLN. RESULTS: Triglyceride solid lipid nanoparticles were quickly prepared by a novel solvent diffusion method in aqueous system. The particles prepared under the condition of ice bath exhibited satisfied particle size and relatively high entrapment efficacy. SLN was separated completely by the centrifuge of 25 000 r &middot min-1 in the acidic dispersed aqueous medium. After burst release at the beginning, a prolonged release was observed. More rapid release profile was achieved by adding 5% and 10% polyethylene glycol (PEG) in SLN in vitro. CONCLUSION: The solid lipid nanoparticles prepared by solvent diffusion method can deliver cyclosporin in a controlled manner.
出处 《中国药学杂志》 EI CAS CSCD 北大核心 2005年第6期444-447,共4页 Chinese Pharmaceutical Journal
关键词 固体脂质纳米粒 环孢素A 甘油三硬脂酸酯 聚乙二醇 Characterization Diffusion Drug dosage Lipids Nanostructured materials Organic solvents Particle size analysis Pharmacokinetics Polyethylene glycols
  • 相关文献

参考文献9

  • 1Muiller RH, Maaben S, Weyhers H, et al. Cytotoxicity of magnetite loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles (SLN)[J].Int JPharm,1996,138(1): 85.
  • 2Heydenreich AV,Westmeier R, Pedersen N, et al. Preparation and purification of cationic solid lipid nanospheres-effects on particle size, physical stability and cell toxicity [J]. Int J Pharm,2003,254:83.
  • 3Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery. Ⅱ. Drug incorporation and physicochemical characterization[J]. J Microencapsul,1999, 16(2): 205.
  • 4Schwarz C, Mehnert W. Freeze-drying of drug free and drug-loaded solid lipid nanoparticle(SLN) [J]. Int J Pharm,1997, 157: 171.
  • 5Saxena V, Sadoqi M, Shao J. Indocyanine green-loaded biodegradable nanoparticles preparation, physicochemical characterization and in vitro release [J]. Int J Pharm,2004,278:293.
  • 6Mühlen AZ, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN)for controlled drug delivery-drug release and release mechanism[J].Eur J Pharm Bioparm, 1998, 45(2) : 149.
  • 7张惠宏,胡富强,袁弘,方明.溶剂扩散法制备丙酸倍氯米松固体脂质纳米粒[J].药学学报,2003,38(4):302-306. 被引量:10
  • 8El-Shabouri MH. Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A [ J ]. Int J Pharm, 2002,249:101.
  • 9Dai JD, Nagai T, Wang TQ, et al. pH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine A[ J]. Irt J Pharm,2004,280:229.

二级参考文献15

  • 1Müller RH, Mder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art [J]. Eur J Pharm Biopharm, 2000,50(1):161-177.
  • 2Yang SC, Zhu JB, Lu Y, et al. Body distribution of camptothecin solid lipid nanoparticles after oral administration [J]. Pharm Res, 1999,16(5):751-757.
  • 3Yang SC, Lu LF, Cai Y, et al. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain [J]. J Controlled Release, 1999,59(3):299-307.
  • 4Müller RH, Maaen S, Weyhers H, et al. Cytotoxicity of magnetite loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles (SLN) [J]. Int J Pharm, 1996,138(1):85-94.
  • 5Müller RH, Lucks JS. Arzneistofftrger aus festen Lipidteilchen, Feste Lipidnanosphren (SLN) [P]. Eur Pat: 0605497,1993-03-25.
  • 6Maaβen S, Schwarz C, Mehnert, et al. Comparison of cytotoxicity between polyester nanoparticles and solid lipid nanoparticles (SLN) [J]. Proc Int Symp Control Release Bioact Mater, 1993,20:490-491.
  • 7Gasco MR. Method for producing solid lipid microspheres having a narrow size distribution [P]. US Pat: 5250236,1993-10-05.
  • 8Mühlen AZ, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism [J]. Eur J Pharm Biopharm, 1998,45(2):149-155.
  • 9Mühlen AZ, Mehnert W. Drug release and release mechanism of prednisolone loaded solid lipid nanoparticles [J]. Pharmazie, 1998,53(8):552-559.
  • 10Kawashima Y, Yamamoto H, Takeuchi H, et al. Properties of a peptide containing DL-lactide/glycolide copolymer nanospheres prepared by novel emulsion solvent diffusion methods [J]. Eur J Pharm Biopharm, 1998,45(1):41-48.

共引文献9

同被引文献74

引证文献5

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部